Company intelligence / Profile preview

CASI Pharmaceuticals, Inc.

Ownership: Public · CASI
Employees: ~233
Development stage: Preclinical

Overview

CASI Pharmaceuticals has commercialized EVOMELA for multiple myeloma in China. The company is developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases, with a focus on addressing antibody-mediated rejection (AMR) in transplant patients.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodiesCAR-T therapySmall molecules
Industry: Biotech

Drug pipeline

12 assets

enmd-2076

11 more assets in the full pipeline.

Request access →

Partnerships

Juventas Cell Therapy Ltd.BioInvent International ABBlack Belt Therapeutics LimitedCleave Therapeutics, Inc.Acrotech Biopharma L.L.C.Mundipharma International Corporation Limited

Financials

Market cap: $2.3M
Total revenue: $3.1M
Enterprise value: $16.5M

Beyond the preview

Go deeper on CASI Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CASI Pharmaceuticals, Inc..

Explore the full profile